BIIB - Biogen Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
344.47
+8.79 (+2.62%)
At close: 4:00PM EDT

344.47 0.00 (0.00%)
After hours: 4:58PM EDT

Stock chart is not supported by your current browser
Previous Close335.68
Open343.12
Bid343.77 x 100
Ask344.52 x 500
Day's Range339.69 - 348.65
52 Week Range244.28 - 348.65
Volume1,508,169
Avg. Volume1,265,795
Market Cap72.83B
Beta0.47
PE Ratio (TTM)22.60
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Two positive calls on this biotech name
    CNBC Videos4 hours ago

    Two positive calls on this biotech name

    Stifel & Mizuho upgraded Biogen to a "buy." The desk debates the calls.

  • It's Friday the 13th, and these are 4 freaky good stocks ...
    CNBC Videos4 days ago

    It's Friday the 13th, and these are 4 freaky good stocks ...

    The “Fast Money” traders share their final trades for the day including Viacom, Biogen, Square and McDonald's.

  • Dow pierces 23,000 as earnings boost the blue chips higher
    Yahoo Finance1 hour ago

    Dow pierces 23,000 as earnings boost the blue chips higher

    The Dow (^DJI) pierces 23,000 after strong earnings beats by UnitedHealth (UNH) and Johnson & Johnson (JNJ), but quickly retreats and settles into a low volume trading range for the balance of the day. Plus, Gary Cohn speaks to Yahoo Finance in Washington, D.C. The president’s chief economist tells us what’s open for negotiation and what’s not. Plus, our prophecy for posterity — or as we usually call it, the look ahead — for everything you need to know about tomorrow with your favorite interlocutor. Catch The Final Round at 3:55 p.m. with Jen Rogers and Yahoo Finance’s Myles Udland and Dan Roberts.

  • MarketWatch46 minutes ago

    Biogen’s stock gets a big boost from 2 upgrades a week before earnings

    Biogen’s stock rallies to 2-year high after two analysts raise their ratings to buy and their price targets to at least $400.

  • Biogen Biomarkers Mark Way To Alzheimer's, Parkinson's Treatments
    Investor's Business Daily5 hours ago

    Biogen Biomarkers Mark Way To Alzheimer's, Parkinson's Treatments

    Biogen eyes therapies for Parkinson's, Alzheimer's and more using biomarkers, biological mechanisms and other cutting-edge technologies.

  • Should You Expect Biogen Inc (BIIB) To Continue Delivering An ROE Of 28.62%?
    Simply Wall St.5 hours ago

    Should You Expect Biogen Inc (BIIB) To Continue Delivering An ROE Of 28.62%?

    With an ROE of 28.62%, Biogen Inc (NASDAQ:BIIB) outpaced its own industry which delivered a less exciting 15.86% over the past year. While the impressive ratio tells us that BIIBRead More...

  • 3 Drug Stocks Hitting 52-Week Highs: Are They Buys?
    Motley Fool10 hours ago

    3 Drug Stocks Hitting 52-Week Highs: Are They Buys?

    2017 has been a great year for these drug stocks. But will their momentum taper off?

  • Barrons.comyesterday

    [$$] More Biotechs That Can Beat Q3 Views

    Credit Suisse Overall, we think most U.S. biotech companies look to be in-line-to-above consensus estimates. Where we have conviction and are focused into quarter: We think Biogen (BIIB) has potential to beat based mostly on Spinraza U.S. trends after reviewing a recent slide deck from the CureSMA website.

  • 6 Top Biotech Companies In Innovation Earn Recognition In New Awards
    Investor's Business Dailyyesterday

    6 Top Biotech Companies In Innovation Earn Recognition In New Awards

    Cancer. Alzheimer’s. MS. Treatments from the fast-growing U.S. biotech industry provide new hope for patients. What are the top biotech companies in innovation?

  • This No. 1-Ranked Medical Stock Is Breaking Out With Q3 Earnings Due
    Investor's Business Daily4 days ago

    This No. 1-Ranked Medical Stock Is Breaking Out With Q3 Earnings Due

    Clinical research firm PRA Health Sciences is testing a new breakout move.

  • Barrons.com4 days ago

    Can Biotech Stay Healthy Through the End of 2017?

    Credit Suisse's Alethia Young and her team take a look at the biotech sector ahead of earnings, writing that they expect large-cap companies' strength to continue through the end of the year. Young writes that she expects most companies to be either in-line or above consensus estimates when they report third-quarter results, as large cap biotechs have been strong heading into t he third quarter. Among stocks where she has the most conviction in the quarter, she thinks that Biogen (BIIB) can beat expectations thanks to Spinraza (it's spinal muscular atrophy drug) trends in the U.S. She writes that she thinks investors should expect a "solid" quarter from Bioverativ (BIVV) as well, and will also be  focusing on sales from Regeneron's (REGN) Dupixent and Gilead's (GILD) HCV franchise.

  • Investopedia5 days ago

    Celgene, Biogen Are Poised to Break Out: A Technical View

    After a period of consolidation, the biotech sector is set to rise again based on technical analysis.

  • Biotech Stock Roundup: Amgen's Imlygic Data Promising, Regeneron Scores Win in PCSK9 Lawsuit
    Zacks6 days ago

    Biotech Stock Roundup: Amgen's Imlygic Data Promising, Regeneron Scores Win in PCSK9 Lawsuit

    With third quarter earnings round the corner, it was a relatively slow week with key updates including Regeneron (REGN) and partner Sanofi's win in the PCSK9 litigation.

  • 5 Pharma & Biotech Stocks That Could Be Big Winners in Q3 Earnings
    Zacks7 days ago

    5 Pharma & Biotech Stocks That Could Be Big Winners in Q3 Earnings

    Here is a look at 5 pharma and biotech stocks including Pfizer (PFE) that are expected to post a positive earnings surprise in Q3.